BRAFV600E Inhibitor Radiosensitizes Thyroid Cancer—Letter
نویسندگان
چکیده
منابع مشابه
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest. MAPK rebound caused by BRAF/MEK inhibitors-induced activation of HER2/HER3 is a resistance mechanism, and combination with HER inhibitor to prevent MAPK rebound may sens...
متن کاملClinical implication of the BRAFV600E mutation in papillary thyroid carcinoma
BACKGROUND The BRAFV600E mutation is the most common genetic alteration in papillary thyroid carcinoma (PTC). In recent studies, the BRAFV600E mutation has been associated with poor clinicopathological characteristics, such as lymph node metastasis, extrathyroidal extension, and advanced stage. However, other studies have failed to establish an association between the BRAFV600E mutation and cli...
متن کاملThe HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
The molecular chaperone HSP90 is involved in stabilization and function of multiple client proteins, many of which represent important oncogenic drivers in NSCLC. Utilization of HSP90 inhibitors as radiosensitizing agents is a promising approach. The antitumor activity of ganetespib, HSP90 inhibitor, was evaluated in human lung adenocarcinoma (AC) cells for its ability to potentiate the effects...
متن کاملPrevalence of BRAFV600E mutation in Asian patients with thyroid cancer
I read with interest the recent article of Navarro-Locsin et al from the Philippines on the local rate of BRAF mutation in thyroid cancer. BRAF is a key genetic event in the initiation and progression of papillary thyroid carcinoma (PTC). It is a well-established diagnostic marker useful in the preoperative evaluation of indeterminate thyroid nodules. In addition, BRAF mutation attracts substan...
متن کاملPostnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
The mutant BRAF (BRAF(V600E)) is the most common genetic alteration in papillary thyroid carcinomas (PTCs). The oncogenicity of this mutation has been shown by some genetically engineered mouse models. However, in these mice, BRAF(V600E) is expressed in all the thyroid cells from the fetal periods, and suppresses thyroid function, thereby leading to TSH elevation, which by itself promotes thyro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2019
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-19-2205